New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
14:45 EDTHTWRHeartWare confirms FDA approval for HeartWare Ventricular Assist System
HeartWare International confirmed that it has received approval from the United States Food and Drug Administration for the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure. The HeartWare System is currently the leading ventricular assist device implanted in patients outside of the United States, having received CE Marking in the European Union in 2009, and Australian Therapeutic Goods Administration approval in 2011. In other clinical development for the HeartWare Ventricular Assist System, HeartWare has completed enrollment of a 450-patient destination therapy study at 50 U.S. sites. The final patients were implanted in May, with a two-year, primary endpoint follow-up period. HeartWare has requested a Continued Access Protocol allocation for destination therapy from the FDA. The company said, "Our team is positioned to commence the commercial rollout of the HeartWare System immediately, first facilitating broad use by the 50 U.S. hospitals that participated in our clinical studies, and then with training and expansion to additional U.S. hospitals."
News For HTWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:00 EDTHTWRHeartWare reports Q3 EPS (64c), consensus (65c)
Subscribe for More Information
October 21, 2014
15:00 EDTHTWRUpdate suggests HeartWare CE mark trial on track, says Wells Fargo
Wells Fargo said the clinicaltrials.gov posting for HeartWare's MVAD CE Mark trial, which had not been changed since April 2013, was updated on October 16 and now indicates the trial is scheduled to start in April 2015. Wells expects HeartWare to update on MVAD on its Q3 call next week, but the firm said that it does not expect any major surprises based on the updated posting. Wells Fargo maintains its Market Perform rating on HeartWare.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use